With the highly variable pRAF and pMEK levels in human tumor cells centered around 5 nM and 500 nM, respectively [20, 21], drugs acting through RAF and MEK inhibitions will be effective only in the cells with relatively low activation. This evidence concerns the gene MAP2K7 and neoplasm.